Pancreatic Cancer Trial, Recruiting NCT06478225 Sponsor: RenJi Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06478225
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study.
  • You are between 18 and 75 years old (any gender).
  • Your doctors expect you to live for at least 3 more months.
  • You are generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
  • You can provide a preserved tissue sample from a biopsy taken within the last 3 years.
  • You have at least one tumor that can be measured on a CT or MRI scan, meeting specific size requirements (confirm with trial site).
  • You have advanced pancreatic cancer confirmed by laboratory testing of tissue or cells, and your cancer has worsened after at least two rounds of standard treatment, you could not tolerate standard treatment due to serious side effects, or no standard treatment is available for you.
  • You have suitable veins for blood collection, with no medical reasons preventing a blood separation procedure.
  • Your blood counts, liver, kidneys, and clotting function are all at acceptable levels as measured by blood tests (confirm with trial site for exact values).
  • If you are able to have children (male or female), you agree to use effective contraception during the study and for 6 months after treatment ends; women who could become pregnant must have a negative pregnancy test within 3 days before starting treatment.

Who may not be able to join:

  • You have cancer that has spread to the brain or central nervous system and is not yet treated or stable.
  • You have HIV, active hepatitis B, active hepatitis C, or active syphilis.
  • You have a mental health condition that would make it difficult to cooperate with treatment or assessments.
  • You have a serious autoimmune disease and have been taking immune-suppressing medication long-term.
  • You have an active or uncontrolled infection requiring treatment within the 14 days before joining the trial.
  • You have certain serious ongoing health conditions, such as unstable heart problems, a recent stroke or heart attack (within 6 months), severe heart failure, serious irregular heartbeat, or uncontrolled high blood pressure.
  • You have significant problems with the functioning of important organs such as the lungs, brain, or kidneys.
  • You have had major surgery or a serious injury within 4 weeks before the cell therapy, or major surgery is planned during the study.
  • You have received chemotherapy, immunotherapy, or certain targeted drug treatments within approximately 1–2 weeks before the blood collection procedure (confirm with trial site for exact timing).
  • You have received CAR-T or TCR-T cell therapy (specialised immune cell treatments) within the last 6 months.
  • You have a history of severe allergies or serious allergic reactions.
  • You currently need blood-thinning (anticoagulant) medication.
  • You are pregnant, breastfeeding, or planning to become pregnant within six months (applies to both men and women).
  • The trial doctors have identified any other reason they feel makes participation unsuitable for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Liwei Wang, Doctorate, RenJi Hospital

Phone: 15850459057

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
7 May 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-Limiting Toxicity (DLT); Maximum Tolerated Dose (MTD); Optimal Biological Dose (OBD); Adverse events (AE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov